IRCT20150808023559N23
Recruiting
Phase 2
Evaluation of safety and effectiveness of favipiravir in comparison with Tenofovir Alafenamid in hospitalized patients with COVID-19
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- COVID-19.
- Sponsor
- Ardabil University of Medical Sciences
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of COVID\-19 based on chest CT scan or positive PCR test for COVID\-19
- •Requiring hospitalization
- •Patient's age between 16 and 100 years
- •Signing informed consent form
Exclusion Criteria
- •Receiving other antiviral medicationsrenal failure
- •Renal failure
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
The evaluation of efficacy of Favipiravir in patients with mild to moderate COVID-19IRCT20201005048936N1Dr. Abidi pharmacutical Co.126
Recruiting
Phase 3
The effects of Favipiravir and Lopinavir/Ritonavir in treatment COVID-19IRCT20200506047323N3Bandare-abbas University of Medical Sciences60
Recruiting
Phase 3
Evaluation of the efficiency and safety of favipiravir + hydroxychloroquine drug regimen in comparison with hydroxychloroquine in hospitalized patients with covid-19IRCT20200428047228N1Quality Improvement of Intensive Care Research Center- Shahid Beheshti University50
Completed
Not Applicable
Investigation on the efficacy and safety of favipiravir in patients who are infected or strongly suspected of being infected with Ebola virusEbola virus diseaseJPRN-UMIN000016101ational Center for Global Health and Medicine5
Recruiting
Phase 3
Evaluation the effects of Favipiravir in COVID-19 patientsCOVID-19 pneumonia.COVID-19, virus identifiedU07.1IRCT20151227025726N14Shahid Beheshti University of Medical Sciences84